FeesSafety
Pluang+

Voyager Therapeutics to present Alzheimer’s gene therapy and antibody data at CTAD 2026.

Market News
27 Oct 2026, 15:01 WIB
GlobeNewsWire
View Source
Bullish
Voyager Therapeutics to present Alzheimer’s gene therapy and antibody data at CTAD 2026.

Voyager Therapeutics announced it will present two poster studies at the 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference in November 2026. The presentations will cover VY1706, a gene therapy aimed at reducing tau protein in the brain, and VY7523, an anti-tau antibody in clinical trials for early Alzheimer's disease. These therapies target tau, a key protein involved in Alzheimer’s progression, highlighting Voyager’s efforts to develop genetic treatments for neurological diseases. The company’s data presentations mark important steps toward clinical validation and potential future treatments for Alzheimer’s patients.

Voyager Therapeutics' Alzheimer’s gene and antibody therapies provide context for health sector performance. For readers following health stocks, here is Pluang's market snapshot as of Oct 27, 2026 17:43 WIB: Of 150 priced US health stocks, 69 rose and 68 fell. HCA Health Inc led with a 5.32% gain at USD 490.00 and a typical hold time of 77 days, contrasting with Nuwellis Inc's 4.90% rise at USD 3.21 but heavy sell pressure (94% sell orders) and a shorter hold time of 29 days. American Well Corp also gained 4.87% at USD 14.20 with a 62-day hold time.

More News

ArcaTrader launches 24/7 perpetuals trading for brokers and prop firms via Hyperliquid.

ArcaTrader launches 24/7 perpetuals trading for brokers and prop firms via Hyperliquid.

ArcaTrader has introduced 24/7 perpetuals trading powered by Hyperliquid on its multi-asset platform, allowing brokers and prop firms to offer continuous perpetuals alongside CFDs through one integrated system. This expansion enhances ArcaTrader's ex...

Others
Bullish
28 minutes ago
Tempus AI reports 23% revenue growth and $193M from new data deals over 5 years

Tempus AI reports 23% revenue growth and $193M from new data deals over 5 years

Tempus AI reported a 23% year-over-year revenue increase to $411.5 million in Q3 2026, driven by rising test prices and multiyear biopharma licensing agreements expected to generate $193 million over five years. The company also anticipates an $80 mi...

Company Fundamentals
Bullish
37 minutes ago
Planet Labs secures new rocket launches from Stoke Space as SpaceX plans to retire Falcon 9 by 2028

Planet Labs secures new rocket launches from Stoke Space as SpaceX plans to retire Falcon 9 by 2028

Planet Labs, which operates the largest Earth observation satellite fleet, faces a challenge as SpaceX plans to retire its Falcon 9 rockets by 2028. To maintain its satellite launches, Planet Labs has signed a multi-launch agreement with Stoke Space ...

Market News
Bullish
42 minutes ago
Sigma Lithium cuts short-term debt 85%, targets 330,000 tons lithium production in 2027 with low costs.

Sigma Lithium cuts short-term debt 85%, targets 330,000 tons lithium production in 2027 with low costs.

Sigma Lithium reduced its short-term debt by 85% through a $125 million convertible note refinancing, easing financial pressure for expansion. The company reported low all-in sustaining costs of $642 per ton, well below the average lithium price of $...

Company Fundamentals
Bullish
1 hour ago
Novartis forecasts 5% sales growth CAGR through 2031 with upgraded peak sales for key drugs.

Novartis forecasts 5% sales growth CAGR through 2031 with upgraded peak sales for key drugs.

Novartis projects a 5% compound annual growth rate (CAGR) in net sales from 2026 to 2031 and aims to restore its core operating income margin to over 40% by 2029. The company raised peak sales forecasts for key drugs Kesimpta, Scemblix, and Leqvio, r...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App